Jasper Therapeutics to Present at Upcoming Conferences

Red Wood City, Calif. — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, announced that the Company will be participating in the following conferences in March.

William Blair’s Innovator Series: What’s Next in Dermatology? (Virtual)

  • Ronald Martell, Chief Executive Officer, will participate in a panel discussing New Therapies in Urticaria.
    • Monday, March 13th, 2023, at 12:00PM ET
    • Registration details available here.

Oppenheimer 33rd Annual Healthcare Conference (Virtual)

  • Ronald Martell, Chief Executive Officer, will give a Corporate Presentation.
    • Monday, March 13th, 2023, at 4:00PM ET
    • Registration details available here.

Details for live and archived webcast will be posted at the Company’s Investor Events webpage.

About Jasper Therapeutics
Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in over 130 dosed subjects and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. In addition, briquilimab is being advanced as a transformational non-genotoxic conditioning agent for gene therapy. For more information, please visit us at www.jaspertherapeutics.com.